Physicians would have to report medical device problems under new bill

A new bill in Congress aimed at changing the Food and Drug Administration’s medical device approval process would require physicians and their practices to report defects or issues with devices, while protecting doctors from being sued over those reports.

The legislation, sponsored by Reps. Mike Fitzpatrick, R-Pa., and Louise Slaughter, D-N.Y., was inspired by reporting problems with laparoscopic power morcellators, used to make tissue removal easier through small incisions and most often used during hysterectomies.

The Wall Street Journal reported that, while there had been discussion of the risks involved with morcellators for years, the FDA didn’t get a formal report about the tools spreading undetected uterine cancer until 2013, when Amy Reed, MD, went public about her own cancer diagnosis related to morcellation in a WSJ article.

Fitzpatrick and Slaughter wrote in a letter introducing the bill that “everyone in chain of care” should have a responsibility to report concerns about devices to the FDA.

“I think everyone would agree that when a medical device is found to be unsafe, there needs to be an effective process in place to track these failures, to remove devices from the market, and provide legal recourse for those impacted. Currently, that process is failing us, and our constituents are paying the price,” Fitzpatrick said in statement. “It’s time we reform the FDA, its processes and procedures to allow for maximum innovation and maximum safety.”

Doctors have been encouraged to report device issues to the FDA, but now physicians and their offices would be mandated to do so. The bill would prevent those reports from being used against physicians in civil litigation.

The FDA declined to comment on the legislation, but say in its statement it wants help from Congress in building a new system to quickly identify safety issues use data generated during patient care. 

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.